Compare VGAS & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VGAS | ICCC |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 55.5M |
| IPO Year | N/A | 1987 |
| Metric | VGAS | ICCC |
|---|---|---|
| Price | $2.61 | $5.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.5K | ★ 20.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.85 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $2.49 | $4.28 |
| 52 Week High | $4.39 | $7.60 |
| Indicator | VGAS | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 55.08 |
| Support Level | $2.49 | $4.72 |
| Resistance Level | $2.79 | $5.36 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 17.65 | 100.00 |
Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.